Effectiveness of a First Mobilization Protocol in Patients Undergoing Knee Arthroplasty: A Randomized Contolled Trial.

J Perianesth NursJul 15, 2026 (epub)
Clinical ResearchOrthopedic Surgery

Ayse Gul Atay Doyğacı, Sevil Guler, Erdinç Esen

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a first mobilization protocol for 78 patients undergoing total knee arthroplasty. The intervention group reported a greater sense of readiness for standing and completed mobilization faster, with significantly lower anxiety and fear levels compared to the control group.

Key findings

  • The intervention group felt more ready for first standing than the control group.
  • Participants in the intervention group completed mobilization in a shorter time.
  • Lower levels of anxiety, stress, and fear of falling were observed in the intervention group.

Why it matters

Effective mobilization protocols can enhance patient readiness and reduce anxiety, potentially leading to improved recovery outcomes after knee arthroplasty. Understanding these dynamics is crucial for optimizing postoperative care.

Source

PubMed · PMID 42455081

Published in J Perianesth Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.